EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Do anti-obesity medical treatments have a direct effect on adipose tissue?

Bruno Vergès

Annales d'Endocrinologie · 2024

DOI: 10.1016/j.ando.2024.05.021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annales d'Endocrinologie, 2024. Verfasst von Bruno Vergès. Beteiligte Einrichtung: Department of Endocrinology-Diabetology, University Hospital, Dijon, France; Inserm, LNR, UMR1231, University of Burgundy and Franche-Comté, Dijon, F…. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Adipose Tissue, Energy Metabolism. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the past years, several drugs have been developed for the treatment of obesity. Some are already used in clinical practice: orlistat, GLP-1 receptor agonists (RA), GLP-1/GIP biagonists and the melanocortin 4 receptor (MC4R) agonist, setmelanotide. Some should be available in the future: GLP-1/glucagon biagonists, GLP-1/GIP/glucagon triagonists. These drugs act mainly by reducing food intake or fat absorption. However, many of them show specific effects on the adipose tissue. All these drugs show significant reduction of fat mass and, more particularly of visceral fat. If most of the drugs, except orlistat, have been shown to increase energy expenditure in rodents with enhanced thermogenesis, this has not yet been clearly demonstrated in humans. However, biagonists or triagonist stimulating glucagon seem to a have a more potent effect to increase thermogenesis in the adipose tissue and, thus, energy expenditure. Most of these drugs have been shown to increase the production of adiponectin and to reduce the production of pro-inflammatory cytokines by the adipose tissue. GLP-1RAs reduce the size of adipocytes and promote their differentiation. GLP-1RAS and GLP-1/GIP biagonists reduce, in the adipose tissue, the expression of several genes involved in lipogenesis. Further studies are still needed to clarify the precise roles, on the adipose tissue, of these drugs dedicated for the treatment of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAnti-Obesity AgentsAdipose TissueEnergy MetabolismHumansAnimalsThermogenesisGlucagon-Like Peptide 1OrlistatGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Adipose tissueDrugGLP-1ObesityTreatment

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide 1OrlistatGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Endocrinology-Diabetology, University Hospital, Dijon, France; Inserm, LNR, UMR1231, University of Burgundy and Franche-Comté, Dijon, France. Electronic address: bruno.verges@chu-dijon.fr.

Zitieren

APA

Vergès, B. (2024). Do anti-obesity medical treatments have a direct effect on adipose tissue?. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2024.05.021

Vancouver

Vergès B. Do anti-obesity medical treatments have a direct effect on adipose tissue?. Annales d'Endocrinologie. 2024. doi:10.1016/j.ando.2024.05.021

BibTeX
@article{Vergs2024,
  author = {Vergès, Bruno},
  title = {Do anti-obesity medical treatments have a direct effect on adipose tissue?},
  journal = {Annales d'Endocrinologie},
  year = {2024},
  doi = {10.1016/j.ando.2024.05.021}
}
Kostenlos starten →